Hormones in Wellness and Disease Prevention: Common Practices, Current State of the Evidence, and Questions for the Future

Primary Care - Clinics in Office Practice

Volumn 35, Issue 4, 2008, Pages 669-705

  Schwartz, Erika T ^a   Holtorf, Kent ^a  

^a NONE   (United States)

Author keywords

Estrogen; Growth hormone; Hormones; Prevention; Progesterone; Testosterone; Thyroid; Wellness

Indexed keywords

AROMATASE; CONJUGATED ESTROGEN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; DIENESTROL; ESCLIM; ESTARATAB; ESTRADIOL; ESTRATEST; ESTROGEN; ETHINYLESTRADIOL; GESTAGEN; GROWTH HORMONE; LEVOTHYROXINE; LEVOTHYROXINE SODIUM; LIOTHYRONINE SODIUM; MEDROXYPROGESTERONE ACETATE; NORETHISTERONE; NORETHISTERONE ACETATE; NORGESTIMATE; ORTHOPRESFEST; PIPERAZINE ESTRONE SULFATE; PLACEBO; PROGESTERONE; PROTIRELIN; TESTOSTERONE; THYROID HORMONE; THYROTROPIN; THYROXINE; UNCLASSIFIED DRUG;

ADD ON THERAPY; ADRENAL GLAND; AGING; ALZHEIMER DISEASE; ANDROGEN DEFICIENCY; ANEMIA; BREAST CANCER; CANCER RISK; CARDIOVASCULAR RISK; CHRONIC DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG CARCINOGENICITY; DRUG EFFECT; DRUG SAFETY; EVENING DOSAGE; EVIDENCE BASED PRACTICE; FREE LIOTHYRONINE INDEX; FREE THYROXINE INDEX; GROWTH HORMONE BLOOD LEVEL; GROWTH HORMONE DEFICIENCY; HEALTH CARE COST; HEART DISEASE; HEART INFARCTION; HORMONE ACTION; HORMONE DEFICIENCY; HORMONE RELEASE; HORMONE SUBSTITUTION; HORMONE SYNTHESIS; HUMAN; HYPOGONADISM; HYPOTHYROIDISM; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTRAABDOMINAL FAT; LIBIDO DISORDER; LOW DRUG DOSE; MALE INFERTILITY; MEDICAL PRACTICE; MENOPAUSAL SYNDROME; METABOLIC SYNDROME X; MONOTHERAPY; MUSCLE MASS; OSTEOPOROSIS; PATIENT EDUCATION; PREVENTIVE MEDICINE; PRIORITY JOURNAL; PROPHYLAXIS; PROSTATE CANCER; PROSTATE HYPERTROPHY; QUALITY OF LIFE; REVIEW; RISK BENEFIT ANALYSIS; SPERMATOZOON COUNT; STABLE ANGINA PECTORIS; STROKE; SUPPLEMENTATION; TESTOSTERONE BLOOD LEVEL; TESTOSTERONE SYNTHESIS; THYROTROPIN BLOOD LEVEL; THYROXINE BLOOD LEVEL; TREADMILL EXERCISE; WELLBEING;

AGING; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; GROWTH HORMONE; HEALTH STATUS; HORMONE REPLACEMENT THERAPY; HORMONES; HUMANS; MENOPAUSE; PRIMARY HEALTH CARE; PRIMARY PREVENTION; PROGESTERONE; QUALITY OF LIFE; RISK FACTORS; TESTOSTERONE; THYROID HORMONES;

EID: 53349143352     PISSN: 00954543     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pop.2008.07.015     Document Type: Review

References (267)

1. Sicotte M.D., Liva S.M., Klutch R., et al. Treatment of multiple sclerosis with the pregnancy hormone estriol. Ann Neurol 52 4 (2002) 421-428
2. Mueck A., Seeger H., and Wallwiener D. Comparison of the proliferative effects of estradiol and conjugated equine estrogens on human breast cancer cells and impact of continuous combined progestogen addition. Climacteric 6 (2003) 221-227
3. Tourgeman D., Gentzchein E., Stanczyk F., et al. Serum and tissue hormone levels of vaginally and orally administered estradiol. Am J Obstet Gynecol 180 6 Part 1 (1999) 1480-1483
4. Lippert T., Seeger H., and Mueck A. Pharmacology and toxicology of different estrogens. G Endodonzia 15 (2001) 26-33
5. Stanzcyk F. Estrogen used for replacement therapy in postmenopausal women. G Endodonzia 15 4 (2001) 17-25
6. Ribot C., and Tremollieres F. Hormone replacement therapy in postmenopausal women. All the treatments are not the same. Gynecol Obstet Fertil 35 (2007) 1-10
7. Schindler A., Campagnoli C., Druckman R., et al. Classification and pharmacology of progestins. Maturitas 46 (2003) S7-S16
8. Smith D., Prentice R., Thompson D., et al. Association of exogenous estrogen and endometrial carcinoma. N Engl J Med 293 23 (1975) 1164-1166
9. Ziel H., and Finkle W. Increased risk of endometrial carcinoma among users of conjugated estrogens. N Engl J Med 293 23 (1975) 1167-1170
10. Stanczyk F.Z. All progestins are not created equal. Steroids 68 (2003) 879-890
11. Mack T.M., Pike M.C., Henderson B.E., et al. Estrogens and endometrial cancer in a retirement community. MEJM 294 23 (1976) 1262-1267
12. Foidart J., Colin C., Denoo X., et al. Estradiol and progesterone regulate the proliferation of human breast epithelial cells. Fertil Steril 69 5 (1998) 963-969
13. Boothby L.A., Doering P.L., and Kipersztok S. Bioidentical hormone therapy: a review. Menopause 11 (2004) 356-367
14. Franke H., and Vermes I. Differential effects of progestogens on breast cancer cell lines. Maturitas 46 (2003) 55-58
15. Druckman R. Progestins and their effects on the breast. Maturitas 46 (2003) 59-69
16. Colditz G. Estrogen, estrogen plus progestin therapy, and risk of breast cancer. Clin Cancer Res 11 (2005) 909-917
17. Callantine M., Martin P., Bolding O.T., et al. Micronined 17β-estradiol for oral estrogen therapy in menopausal women. The Am Col of Obstet Gynecol 46 (1975) 37-41
18. Weiss N., Szekely D., and Austin D. Increasing incidence of endometrial cancer in the United States. NEJM 294 23 (1976) 1259-1262
19. Greenblatt R., and Stoddard L. The estrogen-cancer controversy. J Am Geriatr Soc 26 1 (1978) 1-8
20. Whitehead M., Townsend P., Gill D., et al. Absorption and metabolism of oral progesterone. BMJ 280 6217 (1980) 811-827
21. Morville R., Dray F., Reynier J., et al. Biodisponibilité de la Progestérone Naturelle Administrée Par Voie Orale. Journal De Gynécologie Obstétrique 11 3 (1982) 355-363 [in French]
22. Lane G., Siddle N., Ryder T., et al. Dose dependent effects of oral progesterone on the oestrogenised postmenopausal endometrium. BMJ 287 (1983) 1241-1245
23. Chang K., Fournier S., Lee T., et al. Influences of percutaneous administration of estradiol and progesterone on human breast epithelial cell cycle in vivo. Fertil Steril 63 4 (1995) 785-791
24. Bergkvist L., Adami H., Persson I., et al. The risk of breast cancer after estrogen and estrogen-progestin replacement. NEJM 321 5 (1989) 293-297
25. Glass A., and Hoover R. Rising incidence of breast cancer: relationship to stage and receptor status. Natl Can Inst 82 (1990) 693-696
26. Place V., Powers M., Schenkel L., et al. A double-blind comparative study of estraderm and premarin in the amelioration of postmenopausal symptoms. Am J Obstet Gynecol 152 8 (1985) 1092-1099
27. Riis B., Thomsen K., Strom V., et al. The effect of percutaneous estradiol and natural progesterone on postmenopausal bone loss. Am J Obstet Gynecol 156 1 (1987) 61-65
28. Maxson W., and Hargrove J. Bioavailability of oral micronized progesterone. Fertil Steril 44 5 (1985) 622-626
29. Hargrove J., Maxson W., Wentz A., et al. Menopausal hormone replacement therapy with continuous daily oral micronized estradiol and progesterone. Obstet Gynecol 73 4 (1989) 606-612
30. Whitehead M., Fraser D., Schenkel L., et al. Transdermal administration of oestrogen/progesterone hormone replacement therapy. The Lancet 335 (1990) 310-312
31. Moorjani S., Dupont A., Labrie F., et al. Changes in plasma lipoprotein and apolipoprotein composition in relation to oral versus percutaneous administration of estrogen alone or in cyclic association with utrogestan in menopausal women. J Clin Endocrinol Metab 73 2 (1991) 373-379
32. Erpecum K., van Berge Henegouwen G., Verschoor L., et al. Different hepatobiliary effects of oral and transdermal estradiol in postmenopausal women. Gastroenterology 100 (1991) 482-488
33. Nachtigall L. Emerging delivery systems for estrogen replacement: aspects of transdermal and oral delivery. Am J Obstet Gynecol 173 3 Part 2 (1995) 993-997
34. Writing group for the PEPI trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The postmenopausal estrogen/progestin interventions (PEPI) trial. JAMA 273 (1995) 199-208
35. Thornton K., DeFronzo R., Sherwin R., et al. Micronized estradiol and progesterone: effects on carbohydrate metabolism in reproductive-age women. Society for Gynecologic Investigation 2 4 (1995) 643-652
36. Speroff L., Whitcomb R., Kempfert N., et al. Efficacy and local tolerance of a low-dose, 7-day matrix estradiol transdermal system in the treatment of menopausal vasomotor symptoms. Obstet Gynecol 88 4 (1996) 587-592
37. Evans S., and Davie M. Low and conventional dose transdermal oestradiol are equally effective at preventing bone loss in spine and femur at all post-menopausal ages. Clin Endocrinol 44 (1996) 79-84
38. Good W., John V., Ramirez M., et al. Double-masked, multicenter study of an estradiol matrix transdermal delivery system (Alora™) versus placebo in postmenopausal women experiencing menopausal symptoms. Clin Ther 18 (1996) 1093-1105
39. Ross D., Cooper A., Davies J., et al. Randomized, double-blind, dose-ranging study of the endometrial effects of a vaginal progesterone gel in estrogen-treated postmenopausal women. Am J Obstet Gynecol 177 4 (1997) 937-941
40. Stahlberg C., Pedersen A., Lynge E., et al. Increased risk of breast cancer following different regimens of hormone replacement therapy frequently used in Europe. Int J Cancer 109 (2004) 721-727
41. Nelson H.D. Commonly used types of postmenopausal estrogen for treatment of hot flashes. JAMA 291 13 (2004) 1610-1620
42. Fournier A., Berrino F., Riboli E., et al. Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Int J Cancer 114 (2005) 448-454
43. Fournier A., Berrino F., and Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat 107 1 (2008) 103-111
44. De Lignières B., de Vathaire F., Fournier S., et al. Combined hormone replacement therapy and risk of breast cancer in a French cohort study of 3175 women. Climacteric 5 (2002) 332-340
45. Santen R.J. Risk of breast cancer with progestins: critical assessment of current data. Steroids 68 (2003) 953-964
46. Schairer C., Lubin J., Troisi R., et al. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA 283 (2000) 485-491
47. Campagnali C., Abba C., Ambroggio S., et al. Breast cancer and hormone replacement therapy: putting the risk into perspective. Gynecol Endocrinol 15 (2001) 53-60
48. Lyytinen H., Pukkala E., and Ylikorkala O. Breast cancer risk in postmenopausal women using estrogen-only therapy. Obstet Gynecol 108 6 (2006) 1354-1360
49. Li C., Malone K., Porter P., et al. Relationship between long durations and different regimens of hormone therapy and risk of breast cancer. JAMA 289 24 (2003) 3254-3263
50. Schindler A. European Progestin Club. Differential effects of progestins. Maturitas 46 (2003) S3-S5
51. Grady D., Vittinghoff E., Lin F., et al. Effect of ultra-low-dose transdermal estradiol on breast density in postmenopausal women. Menopause J North Am Men Soc 14 3 (2007) 1-6
52. Simon J.A., Bouchard C., Waldbaum A., et al. Low dose of transdermal estradiol (E2) gel for treatment of symptomatic postmenopausal women. Obstet Gynecol 109 2 (2007) 1-10
53. Montplaisir J., Lorrain J., Denesle R., et al. Sleep in menopause: differential effects of two forms of hormone replacement therapy. Menopause 8 1 (2001) 10-16
54. Gambacciani M., Ciaponi M., Cappagli B., et al. Effects of low-dose, continuous combined hormone replacement therapy on sleep in symptomatic postmenopausal women. Maturitas 50 (2005) 91-97
55. Zegura B., Guzic-Salobir B., Sebestjen M., et al. The effect of various menopausal hormone therapies on markers of inflammation, coagulation, fibrinolysis, lipids, and lipoproteins in healthy postmenopausal women. Menopause 13 4 (2006) 643-650
56. Rossow J., Anderson G., Prentice R., et al. Writing Group for the Women's Health Initiative. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 288 3 (2002) 321-333
57. Wassertheil-Smoller S., Hendrix S., Limacher M., et al. Effects of estrogen plus progestin on stroke in postmenopausal women. The women's health initiative : a randomized trial. JAMA 289 20 (2003) 2673-2684
58. Porch J., Lee I., Cook N., et al. Estrogen-progestin replacement therapy and breast cancer risk: the women's health study (United States). Cancer Causes Control 13 (2002) 847-854
59. Statement on the estrogen plus progestin trial of the Women's Health Initiative. ACOG News release (2002)
60. HERS Study report. HT can relieve menopause-type symptoms common in elderly women. ACOG News Release (2002)
61. Clarke C., and Glaser S. Declines in breast cancer after the WHI: apparent impact of hormone therapy. Cancer Causes Control 18 8 (2007) 847-852
62. Fletcher S., and Colditz G.A. Failure of estrogen plus progestin therapy for prevention. JAMA 288 3 (2002) 366-368
63. Anderson G., Chlebowski R., Rossouw J., et al. Prior hormone therapy and breast cancer risk in the women's health initiative randomized trial of estrogen plus progestin. Maturitas 55 (2006) 1-13
64. Lee S., Kolonel L., and Wilkens L. Postmenopausal hormone therapy and breast cancer risk: the multiethnic cohort. Int. J Cancer 118 (2006) 1285-1291
65. Olsson H., Ingvar C., and Bladstrom A. Hormone replacement therapy containing progestins and given continuously increases breast carcinoma risk in Sweden. Cancer 97 6 (2003) 1387-1392
66. Jernstrom H., Bendahl P., Lidfeldt J., et al. A prospective study of different types of hormone replacement therapy use and the risk of subsequent breast cancer: the Women's Health in the Lund Area (WHILA) study (Sweden). Cancer Causes Control 14 (2003) 673-680
67. Dolan S., and Wilkie N. Arch effects of testosterone administration on human immunodeficiency virus-infected women with low weight. Arch Intern Med 164 (2004) 897-904
68. Davis S., and Walker K. Effects of estradiol with and without testosterone on body composition and relationship with lipids in postmenopausal women. Menopause 7 (2000) 395-401
69. Dobs A., and Nguyen T. Differential effects of oral estrogen versus oral estrogen-androgen replacement therapy on body composition in postmenopausal women. Clin Endocrinol Metab 87 (2002) 1509-1516
70. Miller K., Biller B., and Beauregard C. Effects of testosterone replacement in androgen-deficient women with hypopituitarism; a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab 91 (2006) 1683-1690
71. Davis S., Davidson S., and Donath S. Circulating androgen levels and self-reported sexual function in women. JAMA 294 (2005) 91-96
72. Shifren J., Braunstein G., and Simon J. Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. NEJM 343 (2000) 682-688
73. Ando S., and De Amicis F. Breast cancer from estrogen to androgen receptor. V Mol Molecular and Cellular Endocrinology 193 (2002) 121-128
74. Gammon M., and Thompson W. Polycystic ovaries and the risk of breast cancer. Am J Epidemiol 134 (1991) 818-824
75. Winters J. Current status of testosterone replacement therapy in men. Arch Fam Med 8 (1999) 257-263
76. Mulligan T., Frick M., Zuraw Q., et al. Prevalence of hypogonadism in males aged at least 45 years: the HIM study. Int J Clin Pract 60 7 (2006) 762-769
77. Shippen E., and Fryer W. The testosterone syndrome: the critical factor for energy, health and sexuality-reversing the male menopause (1998), M Evans and company, New York
78. Khaw K., Dowsett M., Folkerd E., et al. Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men. European Prospective Investigation into Cancer in Norfolk (EPIC-Norfolk) prospective population study. Circulation 116 (2007) 2694-2701
79. Shores M.M., Matsumoto A.M., Sloan K.L., et al. Low serum testosterone and mortality in male veterans. Arch Intern Med 166 (2006) 1660-1665
80. English K.M., Steeds R.P., Jones H.T., et al. Low-dose transdermal therapy improves angina theshold in men with chronic stable angina: a randomized, double-blind place-controlled study. Circulation 102 (2000) 1906-1911
81. Kapoor D., Goodwin E., Channer K.S., et al. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol 154 (2006) 899-906
82. Saad F., Gooren L., Haider A., et al. Effects of testosterone gel followed by parenteral testosterone undecanoate on sexual dysfunction and on features of the metabolic syndrome. Andrologia 40 (2008) 44-48
83. Allan C.A., Strauss B.J.G., Burger H.G., et al. Testosterone therapy prevents gain in visceral adipose tissue and loss of skeletal muscle in nonobese aging men. J Clin Endocrinol Metab 93 (2008) 139-146
84. Selvin E., Feinleib M., Zhang L., et al. Androgens and diabetes in men: results from the Third National Health and Nutrition Examination Survey (NHANES III). Diabetes Care 30 2 (2001) 234-238
85. Pitteloud N., Hardin M., Dwyer A.A., et al. Increasing insulin resistance is associated with a decrease in Leydig cell testosterone secretion in men. J Clin Endocrinol Metab 90 (2005) 2636-2641
86. Rodriguez A., Muller D.C., Metter E.J., et al. Aging, androgens, and the metabolic syndrome in a longitudinal study of aging. J Clin Endocrinol Metab 92 9 (2007) 3568-3572
87. Ferrucci L., Maggio M., Bandinelli S., et al. Low testosterone predicts anemia in older adults. Arch Intern Med 166 (2006) 1380-1388
88. Lu P., and Masterman D. Effects of testosterone on cognition, and mood in male patients with mild Alzheimer disease and healthy elderly men. Arch Neurol 63 (2006) 177-185
89. Jackson J., and Kleerekoper M. Osteoporosis in men; diagnosis, pathophysiology and prevention. Medicine 69 (1990) 137-152
90. Behre H., and Kleisch S. Long term effect of testosterone therapy on bone mineral density in hypogonadal men. J Clin Endocrinol Metab 82 (1997) 2386-2390
91. Herbst K., and Bhasin S. Testosterone action on skeletal muscle. Curr Opin Clin Nutr Metab Care 7 3 (2004) 271-277
92. Davidson J., and Camargo C. Effects of androgen on sexual behavior in hypogonadal men. J Clin Endocrinol Metab 48 (1979) 149-161
93. Shabsigh R., Kaufman J., Steidle C., et al. Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. The Journal of Urology 179 5 (2008) S97-S102
94. Saad F., Grahl A.S., Aversa A., et al. Effects of testosterone on erectile function: implications for the therapy of erectile dysfunction. BJU Int 99 5 (2007) 988-992
95. Greco E.A., Spera G., and Aversa A. Combining testosterone and PDE5 inhibitors in erectile dysfunction: basic rationale and clinical evidences. Eur Urol 50 5 (2006) 940-947
96. Huggins C., and Hodges C.V. Studies on prostatic cancer I: the effects of castration, of estrogen and of androgen injection on serum phosphotases in metastatic carcinoma of the prostate. Cancer Res 1 (1941) 293-297
97. Huggins C., Stevens R.E., and Hodges C.V. Studies on prostatic cancer II: the effects of castration on advanced carcinoma of the prostate gland. Arch Surg 43 (1941) 209-223
98. Morgentaler A. Testosterone replacement therapy and prostate cancer. Urol Clin North Am 34 (2007) 555-563
99. Harman S. Testosterone in older men after the Institute of Medicine report: Where do we go from here?. Climacteric 77 5 (2006) 1319-1326
100. Phillips G. Relationship between serum sex hormones and the glucose-insulin-lipid defect in men with obesity. Metabolism 42 1 (1993) 116-120
101. Carruthers M., Trinick T.R., and Wheeler M.J. The validity of androgen assays. The Aging Male 10 3 (2007) 165-172
102. Winters S.J. Endocrine evaluation of testicular function. Endocrinol Metab Clin North Am 23 (1994) 709-723
103. Lazarou S., Reyes-Vallejo L., and Morgentaler A. Wide variability in laboratory reference values for serum testosterone. J Sex Med 3 (2006) 1085-1089
104. Travison T., Araujo A.B., O'Donnell A.B., et al. A population-level decline in serum testosterone levels in American men. J Clin Endocrinol Met 92 1 (2007) 196-202
105. Skakkebæk N.E., Jørgensen N., Main K.M., et al. Is human fecundity declining?. J Androl 29 1 (2006) 2-11
106. Matsumoto A.M. Hormonal therapy of male hypogonadism. Endocrinol Metab Clin North Am 23 (1994) 857-875
107. Carter H.B., Ferrucci L., Kettermann A., et al. Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst 98 21 (2006) 1521-1527
108. Morgentaler A. Commentary: guidelines for male testosterone therapy: a clinician's perspective. J Clin Endocrinol Metab 92 2 (2007) 416-417
109. Maghnie M., Aimaretti G., Bellone S., et al. Diagnosis of GH deficiency in the transition period: accuracy of insulin tolerance test and insulin-like growth factor-I measurement. European Journal of Endocrinology 152 4 (2005) 589-596
110. Gudman D., Kutner M.H., Rogers M., et al. Impaired growth hormone secretion in the adult population. J clin Invest 67 (1981) 1361-1369
111. Zadik Z., Chalew S.A., McCarter R.J., et al. The influence of age on the 24-hour integrated concentration of growth hormone in normal individuals. J Clin Endocrinol Metab 60 (1985) 513-516
112. Ho K.Y., Evans W.S., Blizzard R.M., et al. Effects of sex and age on the 24-hour profile of growth hormone secretion in man: importance of endogenous estradiol concentrations. J Clin Endocrinol Metab 64 (1987) 51-58
113. McGauley G. The psycologogical consequences and quality of life in adults with hormone deficiency. Growth Horm IGF Res 10 (2000) S63-S68
114. Tiryakioaylu O., Kadiolgu P., Canerolgu N.U., et al. Age dependency of serum insulin-like growth factor (IGF)-1 in healthy Turkish adolescents and adults. Indian J Med Sci 57 12 (2003) 543-548
115. Savine R., and Sonksen P. Growth hormone-hormone replacement for the somatopause. Horm Res 53 3 (2000) 37-41
116. Deijen J.B., and van der Veen E.A. The influence of growth hormone (GH) deficiency and GH replacement on quality of life in GH-deficient patients. J Endocrinol Invest 22 5 Suppl (1999) 127-136
117. Murray R.D., Darzy K.H., Gleeson H.K., et al. GH-deficient survivors of childhood cancer: GH replacement during adult life. J Clin Endocrinol Metab 87 1 (2002) 129-135
118. Wureb L., Bengtsson B.A., and Johannsson G. Beneficial effects of long-term GH replacement therapy on quality of life in adults with GH deficiency. Clin Endocrinol 48 (1998) 613-620
119. Gibney J., Wallace J.D., Spinks T., et al. The effects of 10 years of recombinant human growth hormone (GH) in adult GH-deficient patients. J Clin Endocrinol Metab 84 8 (1999) 2596-2602
120. Bennett R.M., Clark S.C., and Walczyk J. A randomized, double-blind, placebo-controlled study of growth hormone in the treatment of fibromyalgia. Am J Med 104 3 (1998) 227-231
121. Johannsson G., Svensson J., and Bengtsson B.A. Growth hormone and ageing. Growth Horm IGF Res 10 2 (2000) 25-30
122. Maison P., and Philippe C. Cardiac effects of growth hormone in adults with growth hormone deficiency: a meta-analysis. Circulation 108 (2003) 2648-2652
123. Cho G.Y., Jeong I.K., Kim S.H., et al. Effect of growth hormone on cardiac contractility in patients with adult onset growth hormone deficiency. Amerasia J 100 6 (2007) 1035-1039
124. Johannsson G., Marin P., Lonn L., et al. GH treatment of abdominally obese men reduces abdominal fat mass, improves glucose and lipoprotein metabolism and reduces diastolic BP. J Clin Endocrinol Metab 82 (1997) 727-734
125. Gotherstrom G., et al. A prospective study of 5 years of GH replacement therapy in GH-deficient adults: sustained effects on body composition, bone mass, and metabolic indices. J Clin Endocrinol Metab 86 10 (2001) 4657-4665
126. Feldt-Rasmussen B., Lange M., Sulowicz W., et al. Growth hormone treatment during hemodialysis in a randomized trial improves nutrition, quality of life, and cardiovascular risk. J Am Soc Nephrol 18 7 (2007) 2161-2171
127. Yuen K.C., and Dunger D.B. Impact of treatment with recombinant human GH and IGF-1 on visceral adipose tissue and glucose homeostasis in adults. Growth Horm IGF Res 16 (2006) S55-S61
128. Aleman A., Verhaar H.J., de Haan E.H., et al. Insulin-like growth factor-1 and cognitive function in healthy older men. J Clin Endocrinol Metab 84 (1999) 471-475
129. Arwert L.I., Veltman D.J., Deijen J.B., et al. Effects of growth hormone substitution therapy on cognitive functioning in growth hormone deficient patients: a functional MRI study. Neuroendocrinology 83 (2006) 12-19
130. Clark R. The somatogenic hormones and insulin-like growth factor-1: stimulators of lymphopoiesis and immune function. Endocr Rev 18 2 (1997) 157-179
131. Burgess W., Liu Q., Jian-Hua Zhou J., et al. The immune-endocrine loop during aging: role of growth hormone and insulin-like growth factor-1. Neuroimmunomodulation 6 1-2 (1999) 56-68
132. Rudman D. Effects of growth hormone in men over 60 years old. N Engl J Med 323 1 (1990) 1-6
133. Munzer T., Harman S.M., Hees P., et al. Effects of GH and/or sex steroid administration on abdominal subcutaneous and visceral fat in healthy aged women and men. J Clin Endocrinol Metab 86 8 (2001) 3604-3610
134. Pfeifer M., Verhovec R., Zizek B., et al. Growth hormone (GH) treatment reverses early atherosclerotic changes in GH-deficient adults. J Clin Endocrinol Metab 84 (1999) 453-457
135. Borson-Chazot F., Serusclat A., Kalfallah Y., et al. Decrease in carotid intima-media thickness after one year growth hormone (GH) treatment in adults with GH deficiency. J Clin Endocrinol Metab 84 (1999) 1329-1333
136. Valimaki M.J., Salmela P.I., Salmi J., et al. Effects of 42 months of GH treatment on bone mineral density and bone turnover in GH-deficient adults. Eur J Endocrinol 140 6 (1999) 545-554
137. Maghnie M., Aimaretti G., Bellone S., et al. Diagnosis of GH deficiency in the transition period: accuracy of insulin tolerance test and insulin-like growth factor-1 measurement. Eur J Endocrinol 152 4 (2005) 589-596
138. Hoeck H.C., Vestergaard P., Jakobsen P.E., et al. Test of growth hormone secretion in adults: poor reproducibility of the insulin tolerance test. Eur J Endo 133 (1995) 305-312
139. Hoeck H.C., Jakobsen P.R., Vestergaard P., et al. Differences in reproducibility and peak growth hormone responses to repeated testing with various stimulators in healthy adults. Growth Horm IGF Res 9 (1999) 18-24
140. Rahim A., Toogood A.A., and Shalet S.M. The assessment of growth hormone status in normal young adult males using a variety of provocative agents. Clin Endo 45 (1996) 557-562
141. Cacciari E., Cicognani A., Pirazzoli P., et al. Differences in somatomedin-C between short-normal subjects and those of nomal height. J Pediatr 106 (1985) 891-894
142. Wilson D.M., and Frane J. A brief review of the use and utility of growth hormone stimulation testing in the NCGS: do we need to do provocative GH testing?. Growth Hormone & IGF Research 15 (2005) S21-S25
143. Tassoni P., Cacciari E., Cau M., et al. Variability of growth hormone response to pharmacological and sleep tests performed twice in short children. J Clin Endocrinol Metab 71 1 (1990) 230-234
144. Gandrud L.M., and Wilson D.M. Is growth hormone stimulation testing in children still appropriate?. Growth Hormone & IGF-1 Research 14 (2004) 185-194
145. Shah A., Stanhope R., and Matthew D. Hazards of pharmacological tests of growth hormone secretion in childhood. BMJ 304 (1992) 173-174
146. Wuster C., Melchinger U., Eversmann T., et al. Reduced incidence of side-effects of growth hormone substitution in 404 patients with hypophyseal insufficiency. Results of a multicenter indications study. Med Klin 93 10 (1998) 585-591
147. Amato G., Izzo G., La Montagna G., et al. Low dose recombinant human growth hormone normalizes bone metabolism and cortical bone density and improves trabecular bone density in growth hormone deficient adults without causing adverse effects. Clin Endocrinol (Oxf) 45 1 (1996) 27-32
148. Chihara K., Koledova E., Shimatsu A., et al. An individualized GH dose regimen for long-term GH treatment in Japanese patients with adult GH deficiency. Eur J Endocrinol 153 1 (2005) 57-65
149. Hankinson S.E., Willett W.C., Colditz G.A., et al. Circulating concentrations of insulin-like growth factor-1 and risk of breast cancer. Lancet 351 9113 (1998) 1393-1398
150. Chan J.M., Stampfer M.J., Giovannucci E., et al. Plasma insulin-like growth factor-1 and prostate cancer risk: a prospective study. Science 279 23 (1998) 563-566
151. Palmqvist R., Hallmans G., Rinaldi S., et al. Plasma insulin-like growth factor 1, insulin-like growth factor binding protein 3, and risk of colorectoal cancer: a prospective study in northern Sweden. Gut 50 (2002) 642-646
152. Agurs-Collins T., Adams-Campbell L.L., Kim K.S., et al. Insulin-like growth factor-1 and breast cancer risk in postmenopausal African-American women. Cancer Detect Prev 24 3 (2000) 199-206
153. Baffa R., Reiss K., El-Gabry E.A., et al. Low serum insulin-like growth factor 1 (IGF-1): a significant association with prostate cancer. Tech Urol 6 3 (2000) 236-239
154. Spitz M.R., Barnett M.J., Goodman G.E., et al. Serum insulin-like growth factor (IGF) and IGF-binding protein levels and risk of lung cancer: a case-control study nested in the beta-carotene and retinol efficacy trial cohort. Cancer Epidemiol Biomarkers Prev 11 11 (2002) 1413-1418
155. Kurek R., Tunn U.W., Eckart O., et al. The significance of serum levels of insulin-like growth factor-1 in patients with prostate cancer. BJU Int 85 1 (2000) 125-129
156. Cutting C.W., Hunt C., Nisbet J.A., et al. Serum insulin-like growth factor-1 is not a useful marker of prostate cancer. BJU Int 83 9 (1999) 996-999
157. Fuhrman B., Barba M., Schünemann H.J., et al. Basal growth hormone concentrations in blood and the risk for prostate cancer: a case control study. Prostate 64 2 (2005) 109-115
158. Chen C., Lewis S.K., Voigt L., et al. Prostate carcinoma incidence in relation to prediagnostic circulating levels of insulin-like growth factor I, insulin like growth factor binding protein 3, and insulin. Cancer 103 1 (2005) 76-84
159. Li B.D., Khosravi M.J., Berkel H.J., et al. Free insulin-like growth factor-I and breast cancer risk. Int J Cancer 91 5 (2001) 736-739
160. Lön S., Inskip P.D., Pollak M.N., et al. Glioma risk in relation to serum levels of insulin-like growth factors. Cancer Epidemiol Biomarkers Prev 16 4 (2007) 844-846
161. Finne P., Auvinen A., Koistinen H., et al. Insulin-like growth factor I is not a useful marker of prostate cancer in men with elevated levels of prostate-specific antigen. J Clin Endocrinol Metab 85 8 (2000) 2744-2747
162. Woodson K., Tangrea J.A., Pollak M., et al. Serum IGF-1: tumor marker or etiologic factor? A prospective study of prostate cancer among Finnish men. Cancer Res 63 14 (2003) 3991-3994
163. Lacey Jr. J.V., Potischman N., Madigan M.P., et al. Insulin-like growth factors, insulin-like growth factor-binding proteins, and endometrial cancer in postmenopausal women: results from a U.S. case-control study. Cancer Epidemiol Biomarkers Prev 13 4 (2004) 607-612
164. Schaffer A., Koushik A., Trottier H., et al. Biomarkers of cervical cancer risk study team. Insulin-like growth factor-I and risk of high-grade cervical intraepithelial neoplasia. Cancer Epidemiol Biomarkers Prev 16 4 (2007) 716-722
165. Serrano M.L., Romero A., Cendales R., et al. Serum levels of insulin-like growth factor-I and -II and insulin-like growth factor binding protein 3 in women with squamous intraepithelial lesions and cervical cancer. Biomedica 26 2 (2006) 258-268
166. Karavitaki N., Warner J.T., Marland A., et al. GH replacement does not increase the risk of recurrence in patients with craniopharyngioma. Clin Endocrinol (Oxf) 64 5 (2006) 556-560
167. Buchfelder M., Kann P.K., Wüster C., et al. Influence of GH substitution therapy in deficient adults on the recurrence rate of hormonally inactive pituitary adenomas: a case control study. European journal of endocrinology 157 2 (2007) 149-156
168. Smit P., and Koppeschaar H. Growth hormone therapy and risk of malignancy. Endocrinologist 18 1 (2008) 39-43
169. Swerdlow A.J., Reddingius R.E., Higgins C.D., et al. Growth hormone treatment of children with brain tumors and risk of tumor recurrence. J Clin Endocrinol Metab 85 12 (2000) 4444-4449
170. Tacke J., Bolder U., Herrmann A., et al. Long-term risk of gastrointestinal tumor recurrence after postoperative treatment with recombinant human growth hormone. J Parenter Enteral Nutr 24 3 (2000) 140-144
171. Critical evaluation of the safety of recombinant human growth hormone administration: statement from the Growth Hormone Research Society. J Clin Endocrinol Metab 86 (2001) 1868-1870
172. Svensson J., Bengtsson B., Rosén T., et al. Malignant disease and cardiovascular morbidity in hypopituitary adults with or without hormone replacement therapy. J Clin Endocrinol Metab 89 7 (2004) 3306-3312
173. Shalet S.M., Brennan B.M., and Reddingius R.E. Growth hormone therapy and malignancy. Horm Res 48 Suppl 4 (1997) 29-32
174. Pollak M. Insulin-like growth factors and prostate cancer. Epidemiol Rev 23 1 (2001) 59-66
175. Leung W., Zhou Y., Hancock M.L., et al. Outcomes of growth hormone replacement therapy in survivors of childhood acute lymphoblastic leukemia. J Clin Oncol 20 13 (2002) 2959-2964
176. Blethen S.L., Allen D.B., Graves D., et al. Safety of recombinant deoxyribonucleic acid-derived growth hormone: the national cooperative growth study experience. J Clin Endocrinol Metab 81 (1996) 1704-1710
177. Frajese G., Drake W.M., Loureiro R.A., et al. Hypothalamopituitary surveillance imaging in hypopituitary patients receiving long-term GH replacement therapy. J Clin Endocrinol Metab 86 11 (2001) 5572-5575
178. Blackman M., Sorkin D.J., Munzer T., et al. Growth hormone and sex steroid administration in healthy aged women and men: a randomized controlled trial. JAMA 288 18 (2002) 2282-2292
179. Yuen K.C., Frystyk J., White D.K., et al. Improvement in insulin sensitivity without concomitant changes in body composition and cardiovascular risk markers following fixed administration of a very low growth hormone (GH) dose in adults with severe GH deficiency. Clin Endocrinol (Oxf) 63 4 (2005) 428-436
180. Yuen K.C., and Dunger D.B. Impact of treatment with recombinant human GH and IGF-1 on visceral adipose tissue and glucose homeostasis in adults. Growth Horm IGF Res 16 (2006) S55-S61
181. Svensson J., Fowelin J., Landin K., et al. Effects of seven years of GH-replacement therapy on insulin sensitivity in GH-deficient adults. J Clin Endocrinol Metab 87 (2002) 2121-2127
182. Ahn C., Kim C., Nam J., et al. Effects of growth hormone on insulin resistance and atherosclerotic risk factors in obese type 2 diabetic patients with poor glycaemic control. Clin Endocrinol 64 (2006) 444-449
183. Canaris G.J., Manowitz N.R., Mayor G., et al. The Colorado thyroid disease prevalence study. Arch Intern Med 160 (2000) 526-534
184. Mcdermott M.T., and Ridgway C. Subclinical hypothyroidism is mild thyroid failure and should be treated. J Clin Endocrinol Met 86 10 (2001) 4585-4590
185. Monzani F., Del Guerra P., Caraccio N., et al. Subclinical hypothyroidism: neurobehavioral features and beneficial effect of l-thyroxine treatment. Clin Invest 71 (1993) 367-371
186. Tappy L., Randin J.P., Schwed P., et al. Prevalence of thyroid disorders in psychogeriatric inpatients. A possible relationship of hypothyroidism with neurotic depression but not dementia. J Am Geriatr Soc 35 (1987) 526-531
187. Joffe R.T., and Levitt A.J. Major depression and subclinical (grade 2) hypothyroidism. Psychoneuroendocrinology 17 (1992) 215-221
188. Haggerty JJ Jr, Stern RA, Mason GA, et al. Subclinical hypothyroidism: a modifiable risk factor for depression? Am J Psychiatry 1993;150(3):508-10.
189. Manciet G., Dartigues J.F., Decamps A., et al. The PAQUID survey and correlates of subclinical hypothyroidism in elderly community residents in the southwest of France. Age Ageing 24 (1995) 235-241
190. Baldini I.M., Vita A., Maura M.C., et al. 1997 Psychological and cognitive features in subclinical hypothyroidism. Prog Neurophychopharmacol Biol Psychiatry 21 (1997) 925-935
191. Ganguli M., Burmeister L.A., Seaberg E.C., et al. Association between dementia and elevated TSH: a community-based study. Biol Psychiatry 40 (1996) 714-725
192. Monzani F., Caraccio N., Siciliano G., et al. Clinical and biochemical features of muscle dysfunction in subclinical hypothyroidism. J Clin Endocrinol Metab 82 (1997) 3315-3318
193. Monzani F., Caraccio N., Del Guerra P., et al. Neuromuscular symptoms and dysfunction in subclinical hypothyroid patients: beneficial effect of L-T4 replacement therapy. Clin Endocrinol 51 (1999) 237-242
194. Misiunas A., Ravera H.N., Faraj G., et al. Peripheral neuropathy in subclinical hypothyroidism. Thyroid 5 (1995) 283-286
195. Goulis D.G., Tsimpiris N., Delaroudis S., et al. Stapedial reflex: a biological index found to be abnormal in clinical and subclinical hypothyroidism. Thyroid 8 (1998) 583-587
196. Ridgway E.C., Cooper D.S., Walker H., et al. Peripheral responses to thyroid hormone before and after L-thyroxine therapy in patients with subclinical hypothyroidism. J Clin Endocrinol Metab 53 (1981) 1238-1242
197. Cooper D.S., Halpern R., Wood L.C., et al. l-thyroxine therapy in subclinical hypothyroidism. Ann Intern Med 101 (1984) 18-24
198. Nystrom E., Caidahl K., Fager G., et al. A double-blind cross-over 12-month study of L-thyroxine treatment of women with 'subclinical' hypothyroidism. Clin Endocrinol 29 (1988) 63-76
199. Bell G.M., Todd W.T., Forfar J.C., et al. End-organ responses to thyroxine therapy in subclinical hypothyroidism. Clin Endocrinol (Oxf) 22 (1995) 83-89
200. Forfar J.C., Wathen C.G., Todd W.T., et al. Left ventricular performance in subclinical hypothyroidism. QJM 57 (1985) 857-865
201. Foldes J., Istvanfy M., Halmagyi M., et al. Hypothyroidism and the heart. Examination of left ventricular function in subclinical hypothyroidism. Acta Med Hung 44 (1987) 337-347
202. Kahaly G.J. Cardiovascular and atherogenic aspects of subclinical hypothyroidism. Thyroid 10 (2000) 665-679
203. Monzani F., Di Bello V., Caraccio N., et al. Effect of levothyroxine on cardiac function and structure in subclinical hypothyroidism: a double blind, placebo-controlled study. J Clin Endocrinol Metab 86 (2001) 1110-1115
204. Hak E.A., Pols H.A., Visser T.J., et al. Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: the Rotterdam study. Ann Intern Med 4 (2000) 270-278
205. Tanis B.C., Westendorp R.G.J., and Smelt A.H.M. Effect of thyroid substitution on hypercholesterolaemia in patients with subclinical hypothyroidism: a re-analysis of intervention studies. Clin Endocrinol 44 (1996) 643-649
206. Danese M.D., Ladenson P.W., Meinert C.L., et al. Effect of thyroxine therapy on serum lipoproteins in patients with mild thyroid failure: a quantitative review of the literature. J Clin Endocrinol Metab 85 (2000) 2993-3001
207. Michalopoulou G., Alevizaki M., Piperingos G., et al. High serum cholesterol levels in persons with 'high normal' TSH levels: Should one extend the definition of subclinical hypothyroidism. Eur J Endocrinol 138 (1998) 141-145
208. Bindels A.J., Westendorp R.G., Frolich M., et al. The prevalence of subclinical hypothyroidism at different total plasma cholesterol levels in middle aged men and women: a need for case-finding?. Clin Endocrinol 50 (1999) 217-220
209. Bakker S.J.L., Ter Matten J.C., Popp-Snijders C., et al. The relationship between thyrotropin and low density lipoprotein cholesterol is modified by insulin sensitivity in healthy euthyroid subjects. J Clin Endocrinol Metab 86 (2001) 1206-1211
210. Lekakis J., Papamichael C., Alevizaki M., et al. Flow-mediated, endothelium-dependent vasodilatation is impaired in subjects with hypothyroidism, borderline hypothyroidism, and high-normal serum thyrotropin (TSH) values. Thyroid 7 (1997) 411-414
211. Walsh J.P., Bremner A.P., Bulsara M.K., et al. Subclinical thyroid dysfunction as a risk factor for cardiovascular disease. Arch Intern Med 165 21 (2005) 2467-2472
212. Peeters R.P., Geyten S.V., Wouters P.J., et al. Tissue thyroid hormone levels in critical illness. J Clin Endocrinol Metab 12 (2005) 6498-6507
213. Docter R., Krenning E.P., de Jong M., et al. The sick euthyroid syndrome: changes in thyroid hormone serum parameters and hormone metabolism. Clin Endocrinol (Oxf) 39 (1993) 499-518
214. Fliers E., Alkemade A., and Wiersinga W.M. The hypothalamic-pituitary-thyroid axis in critical illness. Best Practice & Research Clinical Endocrinology & Metabolism 15 4 (2001) 453-464
215. Chopra I.J. Euthyroid sick syndrome: Is it a misnomer?. J Clin Endocrinol Metab 82 2 (1997) 329-334
216. van der Poll T., Romijn J.A., Wiersinga W.M., et al. Tumor necrosis factor: a putative mediator of the sick euthyroid syndrome in man. J Clin Endocrinol Metab 71 6 (1990) 1567-1572
217. Stouthard J.M., van der Poll T., Endert E., et al. Effects of acute and chronic interleukin-6 administration on thyroid hormone metabolism in humans. J Clin Endocrinol Metab 79 5 (1994) 1342-1346
218. Corssmit E.P., Heyligenberg R., Endert E., et al. Acute effects of interferon-alpha administration on thyroid hormone metabolism in healthy men. Clin Endocrinol Metab 80 11 (1995) 3140-3144
219. Nagaya T., Fujieda M., Otsuka G., et al. A potential role of activated NF-Kappa B in the pathogenesis of euthyroid sick syndrome. J Clin Invest 106 3 (2000) 393-402
220. Bianco A.C., Salvatore D., Gereben B., et al. Biochemistry, cellular and molecular biology, and physiological roles of the iodothyronine selenodieidinases. Endocr Rev 23 (2002) 38-89
221. Chopra I.J., Huang T.S., Beredo A., et al. Evidence for an inhibitor of extrathyroidal conversion of thyroxine to 3,5,3'-triiodothyronine in sera of patients with nonthyroidal illnesses. J Clin Endocrinol Metab 60 (1985) 666-672
222. Peeters R.P., Wouters P.J., Kaptein E., et al. Reduced activation and increased inactivation of thyroid hormone in tissues of critically ill patients. J Clin Endocrinol Metab 88 (2003) 3202-3211
223. Chopra I.J., Chopra U., Smith S.R., et al. Reciprocal changes in serum concentrations of 3,3',5-triiodothyronine (T3) in systemic illnesses. J Clin Endocrinol Metab 41 (1975) 1043-1049
224. Iervasi G., Pinitore A., Landi P., et al. Low-T3 syndrome a strong prognostic predictor of death in patients with heart disease. Circulation 107 5 (2003) 708-713
225. Peeters R.P., Wouters P.J., van Toor H., et al. Serum 3,3',5'-triiodothyronine (rT3) and 3,5,3'-triiodothyronine/rT3 are prognostic markers in critically ill patients and are associated with postmortem tissue deiodinase activities. J Clin Endocrinol Metab 90 8 (2005) 4559-4565
226. Wartofsky L., and Burman K. Alterations in thyroid function in patients with systemic illness; the "euthyroid sick syndrome". Endocr Rev 3 2 (1982) 164-217
227. Hennemann G., Everts M.E., de Jong, et al. The significance of plasma membrane transport in the bioavailability of thyroid hormone. Clin Endocrinol 48 (1998) 1-8
228. Vos R.A., de Jong M., Bernard H.F., et al. Impaired thyroxine and 3,5,3'-triodothyronine handling by rat hepatocytes in the presence of serum of patients with non-thryoidal illness. J Clin Endocrinology met 80 (1995) 2364-2370
229. Chopra I.J., Solomon D.H., Hepner G.W., et al. Misleadingly low free thyroxine index and usefulness of reverse triiodothyronine measurement in nonthyroidal illnesses. Ann Intern Med 90 6 (1979) 905-912
230. De Jong M., Docter R., Van Der Hoek H.J., et al. Transport of 3,5,3'-triiodothyronine into the perfused rat liver and subsequent metabolism are inhibited by fasting. Endocrinology 131 (1992) 463-470
231. Mooradian A.D., Reed R.L., Osterweil D., et al. Decreased serum triiodothyronine is associated with increased concentrations of tumor necrosis factor. J Clin Endocrinol Metab 71 5 (1990) 1239-1242
232. de Jong F., den Heijer T., Visser T.J., et al. Thyroid hormones, dementia, and atrophy of the medical temporal lobe. J Clin Endocrinol Met 91 7 (2006) 2569-2573
233. Carrero J.J., Qureshi A.R., Axelsson J., et al. Clinical and biochemical implications of low thyroid hormone levels (total and free forms) in euthyroid patients with chronic kidney disease. J Intern Med 262 (2007) 690-701
234. Zoccali C., Tripepi G., Cutrupi S., et al. Low triiodothyronine: a new facet of inflammation in end-stage renal disease. J Am Soc Nephrol 16 (2005) 2789-2795
235. Zoccali C., Mallamaci F., Tripepi G., et al. Low triiodothyronine and survival in end-stage renal disease. Kidney Int 70 (2006) 523-528
236. Naslund E., Andersson I., Degerblad M., et al. Associations of leptin, insulin resistance and thyroid function with long-term weight loss in dieting obese men. J Int Med 248 (2000) 299-308
237. Pingitore A., Landi P., Taddei M.C., et al. Triiodothyronine levels for risk stratification of patients with chronic heart failure. Am J Med 118 2 (2005) 132-136
238. Kozdag G., Ural D., Vural A., et al. Relation between free triiodothyronine/free thyroxine ratio, echocardiographic parameters and mortality in dilated cardiomyopathy. Eur J Heart Fail 7 1 (2005) 113-118
239. Karadag F., Ozcan H., Karul A.B., et al. Correlates of non-thyroidal illness syndrome in chronic obstructive pulmonary disease. Respir Med 101 (2007) 1439-1446
240. Kok P., Roelfsema F., Langendonk J.G., et al. High circulating thyrotropin levels in obese women are reduced after body weight loss induced by caloric restriction. J Clin Endocrinol Metab 90 (2005) 4659-4663
241. Ohyama T., Aono T., Nakai A., et al. Circulation free T3 in pregnancy, liver disease, diabetes mellitus and thyroid disease. Nippon Naibunpi Gakkai Zasshi 60 (1984) 1227-1234
242. Parr J.H. The effect of long-term metabolic control on free thyroid hormone levels in diabetics during insulin treatment. Ann Clin Biochem 24 5 (1987) 466-469
243. Dimopoulou I., Ilias I., Mastorakos G., et al. Effects of severity of chronic obstructive pulmonary disease on thyroid function. Metabolism 50 12 (2001) 1397-1401
244. Mariotti S., Barbesino G., Caturegli P., et al. Complex alterations of thyroid function in healthy centenarians. J Clin Endocrinol Met 77 5 (1993) 1130-1134
245. Nomura S., Pittman C.S., Chambers J.B., et al. Reduced peripheral conversion of thyroxine to triiodothyronine in patients with hepatic cirrhosis. J Clin Invest 56 (1975) 643-648
246. Pingitore A., Galli E., Barison A., et al. Acute effects of triiodothyronine replacement therapy in patients with chronic heart failure and low T3 syndrome: a randomized placebo-controlled study. J Clin Endocrinol Met 93 (2008) 1351-1358
247. Dulchavsky S.A., Kennedy P.R., Geller E.R., et al. T3 preserves respiratory function in sepsis. J Trauma 31 (1991) 753-759
248. Hesch R.D., Husch M., Kodding R., et al. Treatment of dopamine-dependent shock with triiodothyronine. Endocr Res Commun 8 (1981) 299-301
249. Dulchavsky S.A., Hendrick S.R., and Dutta S. Pulmonary biophysical effects of triidothyronine (T3) augmentation during sepsis-induced hypothyroidism. J Trauma 35 (1993) 104-109
250. Meyer T., Husch M., van den Berg E., et al. Treatment of dopamine-dependent shock with triiodothyronine: preliminary results. Dtsch Med Wochenschr 104 (1979) 1711-1714
251. Novitzky D., Cooper D.K., and Reichart B. Hemodynamic and metabolic responses to hormonal therapy in brain-dead potential organ donors. Transplantation 43 (1987) 852-855
252. Dulchavsky S.A., Maitra S.R., Maurer J., et al. Beneficial effects of thyroid hormone administration on metabolic and hemodynamic function in hemorrhagic shock. FASEB J 4 (1990) A952
253. Hamilton M.A., Stevenson L.W., Fonarow G.C., et al. Safety and hemodynamic effects of intravenous triiodothyronine in advanced congestive heart failure. Am J Cardiol 81 (1998) 443-447
254. Klemperer J.D., Klein I.L., Ojamaa K., et al. Triidothyronine therapy lowers the incidence of atrial fibrillation after cardiac operations. Ann Thorac Surg 61 (1996) 1323-1329
255. Smidt-Ott U.M., and Ascheim D.D. Thyroid hormone and heart failure. Curr Heart Fail Rep 3 (2006) 114-119
256. Carle A., Laurberg P., Pedersen I.B., et al. Thyrotropin secretion decreases with age in patients with hypothyroidism. Clinical Thyroidology 17 (2007) 139-144
257. van den Beld A.W., Visser T.J., Feelders R.A., et al. Thyroid hormone concentrations, disease, physical function and mortality in elderly men. J Clin Endocrinol Metab 90 12 (2005) 6403-6409
258. Hermann J., Heinen E., Kroll H.J., et al. Thyroid function and thyroid hormone metabolism in elderly people low T3-syndrome in old age. Klin Wochenschr 59 (1981) 315-323
259. Fukagawa N.K., Bandini L.G., and Young J.B. Effect of age on body composition and resting metabolic rate. Am J Physiol Endocrinol Metab 259 (1990) E233-E238
260. van Coevorden A., Laurent E., Decoster C., et al. Decreased basal and stimulated thyrotropin secretion in healthy elderly men. J Clin Endocrinol Metab 69 (1989) 177-185
261. Rubenstein H.A., Butler V.P.J., and Werner S.C. Progressive decrease in serum triiodothyronine concentrations with human aging: radioimmunoassay following extraction of serum. J Clin Endocrinol Metab 37 (1973) 247-253
262. Chakraborti S., Chakraborti T., Mandal M., et al. Hypothalamic-pituitary-thyroid axis status of humans during development of ageing process. Clin Chim Acta 288 1-2 (1999) 137-145
263. Piers L.S., Soars M.J., McCormack L.M., et al. Is there evidence for an age-related reduction in metabolic rate?. J Appl Phys 85 (1998) 2196-2204
264. Poehlman E.T., Berke E.M., Joseph J.R., et al. Influence of aerobic capacity, body composition, and thyroid hormones on the age-related decline in resting metabolic rate. Metabolism 41 (1992) 915-921
265. Magri F., Fioravanti C.M., vignati G., et al. Thyroid function in old and very old healthy subjects. J Endocrinol Invest 25 10 (2002) 60-63
266. Goichot B., Schlienger J.L., Grunenberger F., et al. Thyroid hormone status and nutrient intake in the free-living elderly. Interest of reverse triiodothyronine assessment. Eur J Endocrinol 130 (1994) 244-252
267. Cizza G., Brady L.S., Calogero A.E., et al. Central hypothyroidism is associated with advanced age in male Fischer 344/n rats: in vivo and in vitro studies. Endocrinology 131 (1992) 2672-2680